Screener
Immunome
IMNMImmunome is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies.
Earnings
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$181.8K
EPS estimate-$0.64
Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Immunome is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies. The company leverages deep expertise in antibody-drug conjugates (ADCs) and radioligand therapies to build a pipeline of differentiated assets for the treatment of solid tumors and hematologic malignancies.
Competitive position
Immunome is an emerging player in the ADC space, led by a management team with a track record of commercializing early-generation targeted therapies.
GeographiesGlobal, United States
Customer segmentsOncology patients, Clinical trial participants
Business modelR&D intensive, Biopharmaceutical drug development
SuppliersThird-party diagnostic radiotracer suppliers, Contract manufacturing organizations, Specialized chemical and biological raw material providers
CustomersHospitals, Oncology clinics, Pharmaceutical distributors
CountryUnited States of America
Listed2020
Employees62.0
CEOClay Siegall
SectorHealthcare
IndustryBiotechnology
Websiteimmunome.com
FilingsSEC EDGAR
FAQ
- What is Immunome's market cap?
- Immunome (IMNM) has a market capitalization of $3.3B and trades on NASDAQ.
- Who are Immunome's competitors?
- Immunome's key competitors include Seagen, Arcus Biosciences, Inc., Greenwich LifeSciences, Inc., and others. These companies compete in similar markets and product categories.
- Who does Immunome partner with?
- Immunome's notable partners include Ayala Pharmaceuticals.
- Where is Immunome headquartered?
- Immunome is headquartered in United States of America and employs approximately 62 people. It has been publicly traded since 2020.